Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase‐1, C/EBP‐β and ILAD‐1, a novel gene with homology to arrestins
Open accessAbstract
We recently demonstrated that the potent hallucinogenic drug lysergic acid diethylamide (LSD) dynamically influences the expression of a small collection of genes within the mammalian prefrontal cortex. Towards generating a greater understanding of the molecular genetic effects of hallucinogens and how they may relate to alterations in behavior, we have identified and characterized expression patterns of a new collection of three genes increased in expression by acute LSD administration. These genes were identified through additional screens of Affymetrix DNA microarrays and examined in experiments to assess dose–response, time course and the receptor mediating the expression changes. The first induced gene, C/EBP‐β, is a transcription factor. The second gene, MKP‐1, suggests that LSD activates the MAP (mitogen activated protein) kinase pathway. The third gene, ILAD‐1, demonstrates sequence similarity to the arrestins. The increase in expression of each gene was partially mediated through LSD interactions at 5‐HT 2A (serotonin) receptors. There is evidence of alternative splicing at the ILAD‐1 locus. Furthermore, data suggests that various splice isoforms of ILAD‐1 respond differently at the transcriptional level to LSD. The genes thus far found to be responsive to LSD are beginning to give a more complete picture of the complex intracellular events initiated by hallucinogens.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Findings from in vivo studies investigating acute effects of a single dose of 5-MeO-DMT, DMT, psilocybin, and LSD (37%) suggest altered cellular plasticity of structural and functional nature.
“Findings from in vivo studies investigating acute effects of a single dose of 5-MeO-DMT, DMT, psilocybin, and LSD (37%) suggest altered cellular plasticity of structural and functional nature (54–60).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [59]
The Discussion (pp. 581–583) reports acute LSD-induced expression of genes associated with synaptic plasticity, and the paper suggests these changes could have longer-term neuromodulatory effects. It does not demonstrate structural or functional plasticity after LSD; it measures gene expression. This source addresses LSD, not the other drugs grouped with it in the multi-citation sentence. (LLM, conf=0.82)
Experimental — accuracy not yet measuredA single dose of LSD (0.20, 0.24, 0.5, 1.0 mg/kg i.p.) stimulated the mRNA expression of plasticity-promoting genes in the cortex of rats and mice, within 1-2 h after administration and in a time- and dose-dependent manner.
“A single dose of LSD (0.20, 0.24, 0.5, 1.0 mg/kg i.p.) stimulated the mRNA expression of plasticity-promoting genes in the cortex of rats and mice, within 1–2 h after administration and in a time- and dose-dependent manner (56–59).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [59]
The Animals, Dose-response, and Time course sections (page numbers not provided) describe single-dose LSD experiments in rat prefrontal cortex at 0.2, 0.5, and 1.0 mg/kg, with dose-dependent expression and peaks at 45 or 90 minutes. The paper does not report mouse experiments or a 0.24 mg/kg dose. It describes the genes as implicated in synaptic plasticity, but does not establish that their increased expression promotes plasticity. (LLM, conf=0.88)
Experimental — accuracy not yet measuredPreclinical evidence suggests a dose-dependent effect on increases in the expression of some neuroplasticity-related genes induced by serotonergic psychedelics.
“preclinical evidence suggests a dose-dependent effect on increases in the expression of some neuroplasticity-related genes induced by serotonergic psychedelics [73–75]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ferguson, S. S. G. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01478-9 · Cited by 1,827 · see citing works
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
Mammalian Gene Collection (MGC) Program Team* (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242603899 · Cited by 1,742 · see citing works
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784 · see citing works
Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y., Sono, H., Gon, Y., & Yodoi, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21645 · Cited by 730 · see citing works
Araneda, R. C., & Andrade, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90128-b · Cited by 621 · see citing works
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · see citing works
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · see citing works
Aghajanian, G. K., & Marek, G. J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01224-x · Cited by 376 · see citing works
Aghajanian, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00135-3 · Cited by 371 · see citing works
Martín‐Ruiz, R., Puig, M. V., Celada, P., Shapiro, D. A., Roth, B. L., Mengod, G., & Artigas, F. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09856.2001 · Cited by 338 · see citing works
Chen, K.-S., & DeLuca, H. F. (1994) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(94)90242-9 · Cited by 321 · see citing works
Slack, D. N., Seternes, O. M., Gabrielsen, M., & Keyse, S. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010966200 · Cited by 269 · see citing works
Aghajanian, G. K., & Marek, G. (1999) · Neuropsychopharmacology · doi:10.1038/sj.npp.1395318 · Cited by 199 · see citing works
Taubenfeld, S. M., Wiig, K. A., Monti, B., Dolan, B., Pollonini, G., & Alberini, C. M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00084.2001 · Cited by 179 · see citing works
Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene.
Kwak, S., Hakes, D. J., Martell, K. J., & Dixon, J. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41905-3 · Cited by 168 · see citing works
Kurrasch‐Orbaugh, D. M., Watts, V. J., Barker, E. L., & Nichols, D. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.042184 · Cited by 166 · see citing works
Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · see citing works
Self-citationBokemeyer, D., Sorokin, A., Yan, M., Ahn, N. G., Templeton, D. J., & Dunn, M. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.639 · Cited by 157 · see citing works
McBindall—A Better Name for CCAAT/Enhancer Binding Proteins?
McKnight, S. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00543-8 · Cited by 152 · see citing works
Kurrasch‐Orbaugh, D. M., Parrish, J. C., Watts, V. J., & Nichols, D. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01921.x · Cited by 138 · see citing works
Ujike, H., Takaki, M., Kodama, M., & Kuroda, S. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04151.x · Cited by 121 · see citing works
Regulatory roles of thioredoxin in oxidative stress-induced cellular responses
Nishinaka, Y., Masutani, H., Nakamura, H., & Yodoi, J. (2001) · Redox Report · doi:10.1179/135100001101536427 · Cited by 101 · see citing works
Nichols, D. E., Frescas, S. P., Marona‐Lewicka, D., & Kurrasch‐Orbaugh, D. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020153s · Cited by 91 · see citing works
Krebs-Thomson, K. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00164-4 · Cited by 87 · see citing works
Cortés‐Canteli, M., Pignatelli, M., Santos, Á., & Pérez‐Castillo, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108761200 · Cited by 85 · see citing works
Nichols, C. D., Garcia, E. E., & Sanders-Bush, E. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00029-9 · Cited by 82 · see citing works
Self-citation[3H]MDL 100,907: a novel selective 5-HT2A receptor ligand
Johnson, M., Siegel, B., & Carr, A. (1996) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00178722 · Cited by 80 · see citing works
The Paradox of 5-Methoxy-N,N-Dimethyltryptamine
Winter, J. C., Filipink, R. A., Timineri, D. M., Helsley, S., & Rabin, R. A. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00178-1 · Cited by 79 · see citing works
Backstrom, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00005-6 · Cited by 56 · see citing works
Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action
Marek, G. J., & Aghajanian, G. K. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00076-3 · Cited by 40 · see citing works
Critchley, D. J. P., Childs, K. J., Middlefell, V. C., & Dourish, C. T. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90642-4 · Cited by 36 · see citing works
Yamamoto, Y., Sakamoto, M., Fujii, G., Kanetaka, K., Asaka, M., & Hirohashi, S. (2001) · PubMed · Cited by 29 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [11]11. Freedman D. X. (1984) LSD: the Bridge from Human to Animal, pp. 203-226. Raven Press, New York.
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
The Interaction of Thioredoxin with Txnip
Patwari, P., Higgins, L., Chutkow, W. A., Yoshioka, J., & Lee, R. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600427200 · Cited by 320 · see citing works
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303 · see citing works
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313 · see citing works
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276 · see citing works
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269 · see citing works
On the origins of arrestin and rhodopsin
Alvarez, C. E. (2008) · BMC Evolutionary Biology · doi:10.1186/1471-2148-8-222 · Cited by 242 · see citing works
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239 · see citing works
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
Kuypers, K., Ng, L., Erritzoe, D., Knudsen, G., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119857204 · Cited by 188 · see citing works
Self-citationPsychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · see citing works
Self-citationBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 135 · see citing works
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127 · see citing works
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
Gregorio, D. D., Comai, S., Posa, L., & Gobbi, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111953 · Cited by 124 · see citing works
Chronic pain and psychedelics: a review and proposed mechanism of action
Castellanos, J. P., Woolley, C., Bruno, K. A., Zeidan, F. Z., Halberstadt, A. L., & Furnish, T. J. (2020) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2020-101273 · Cited by 119 · see citing works
Han, S., Kommaddi, R. P., & Shenoy, S. K. (2012) · EMBO Reports · doi:10.1038/embor.2012.187 · Cited by 117 · see citing works
C/EBPβ and C/EBPδ transcription factors: Basic biology and roles in the CNS
Pulido-Salgado, M., Vidal-Taboada, J. M., & Saura, J. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.06.003 · Cited by 116 · see citing works
De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110 · see citing works
Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 92 · see citing works
Kozłowska, U., Nichols, C. D., Wiatr, K., & Figiel, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15509 · Cited by 80 · see citing works
Self-citationThe Arrestin Fold: Variations on a Theme
Aubry, L., Guetta, D., & Klein, G. (2009) · Current Genomics · doi:10.2174/138920209787847014 · Cited by 74 · see citing works
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 67 · see citing works
Shea, F. F., Rowell, J., Li, Y., Chang, T., & Alvarez, C. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050557 · Cited by 68 · see citing works
Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia
Martin, D. A., Marona-Lewicka, D., Nichols, D. E., & Nichols, C. D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.013 · Cited by 67 · see citing works
Self-citationWeiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 68 · see citing works
Roth, B. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.012 · Cited by 66 · see citing works
An animal model of schizophrenia based on chronic LSD administration: Old idea, new results
Marona‐Lewicka, D., Nichols, C. D., & Nichols, D. E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.006 · Cited by 65 · see citing works
Self-citationPsychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 65 · see citing works
Guarnieri, D. J., Brayton, C. E., Richards, S., Maldonado‐Avilés, J. G., Trinko, R., Nelson, J. C., Taylor, J. R., Gourley, S. L., & Dileone, R. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.06.028 · Cited by 51 · see citing works
The Effects of Hallucinogens on Gene Expression
Martin, D. A., & Nichols, C. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_479 · Cited by 51 · see citing works
Self-citationThe role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 46 · see citing works
Identification of neuronal target genes for CCAAT/Enhancer Binding Proteins
Kfoury, N., & Kapatos, G. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.11.004 · Cited by 44 · see citing works
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 38 · see citing works
α-Arrestins and Their Functions: From Yeast to Human Health
Zbieralski, K., & Wawrzycka, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094988 · Cited by 44 · see citing works
Hu, J., Kapoor, M., Zhang, W., Hamilton, S. R., & Coombes, K. R. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti592 · Cited by 34 · see citing works
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 32 · see citing works
de Abreu, M. S., Giacomini, A. C. V. V., Demin, K. A., Galstyan, D. S., Zabegalov, K. N., Kolesnikova, T. O., Amstislavskaya, T. G., Strekalova, T. V., Petersen, E. V., & Kalueff, A. V. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173205 · Cited by 31 · see citing works
Novel Microarray-Based Method for Estimating Exposure to Ionizing Radiation
Gruel, G., Lucchesi, C., Pawlik, A., Frouin, V., Alibert, O., Kortulewski, T., Zarour, A., Jacquelin, B., Gidrol, X., & Roux, D. T. (2006) · Radiation Research · doi:10.1667/rr0260.1 · Cited by 22 · see citing works
Schindler, E. A. D., Dave, K. D., Smolock, E. M., Aloyo, V. J., & Harvey, J. A. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.12.002 · Cited by 20 · see citing works
Lysergic acid diethylamide induces increased signalling entropy in rats’ prefrontal cortex
Savino, A., & Nichols, C. D. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15534 · Cited by 19 · see citing works
Self-citationMind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 18 · see citing works
Jee, C., Choi, T.-W., Kalichamy, K., Yee, J. Z., Song, H., Ji, Y. J., Lee, J., Lee, J. I., L’Étoile, N. D., Ahnn, J., et al. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.012 · Cited by 14 · see citing works
Iaria, G., Fox, C. J., Scheel, M., Stowe, R., & Barton, J. J. S. (2009) · Neurocase · doi:10.1080/13554790903329141 · Cited by 14 · see citing works
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05502-y · Cited by 13 · see citing works
“First, preclinical evidence suggests a dose-dependent effect on increases in the expression of some neuroplasticity-related genes induced by serotonergic psychedelics [73–75], a key proposed therapeutic mechanism [44, 45].”
BackgroundDolder, P. C., Grünblatt, E., Müller, F., Borgwardt, S., & Liechti, M. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00423 · Cited by 12 · see citing works
Kim, S. H., Yu, H. S., Park, H. G., Park, S., Seo, M. S., Jeon, W. J., Ahn, Y. M., Ha, K., Shin, S. Y., & Kim, Y. S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3165-y · Cited by 9 · see citing works
Weiss, R., Bitton, A., Nahary, L., Arango, M., Benhar, I., Blank, M., Shoenfeld, Y., & Chapman, J. (2016) · Immunologic Research · doi:10.1007/s12026-016-8840-8 · Cited by 9 · see citing works
Fortwengel, G. (2003) · KARGER eBooks · doi:10.1159/000074701 · Cited by 7 · see citing works
The Role of Mental Imagery in Aberrant Perception: A Neurobiological Perspective
van de Ven, V. G., & Linden, D. E. J. (2012) · Journal of Experimental Psychopathology · doi:10.5127/jep.017511 · Cited by 6 · see citing works
Myers, M. G., & Toal, C. B. (1995) · PubMed · Cited by 6 · see citing works
Zahid, Z., Sultan, Z. W., Krause, B. M., Wenthur, C. J., Pearce, R. A., & Banks, M. I. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0061 · Cited by 4 · see citing works
D-Lysergic Acid Diethylamide (LSD) Investigator's Brochure
Jerome, L. (2008) · Cited by 4 · see citing works
Bender, D. A., & Siegel, J. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00043-9 · Cited by 3 · see citing works
Zhang, J., Lin, C., Lv, X., Zhao, H., & Wang, X. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.02.011 · Cited by 2 · see citing works
Jerome, L. (2007) · Cited by 2 · see citing works
LSD induces increased signalling entropy in rats’ prefrontal cortexPreprint
Savino, A., & Nichols, C. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449556 · Cited by 2 · see citing works
Self-citationIbrahem, W., Kassem, S., & El-Gohary, M. (2005) · Cited by 1 · see citing works
Simpson, S. A. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316556702.004 · Cited by 1 · see citing works
Vanderijst, L., Hever, F., Buot, A., Dauré, C., Benoit, J., Hanak, C., Veeser, J., Morgiève, M., Campanella, S., Kornreich, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3829237/v1
LSD (Lysergic Acid Diethylamide)
Krishnan, J. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815223828124010005
Gojani, E. G., Farzin, H., Sutherland, R. J., & Mohajerani, M. H. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106619
- Authors
- Nichols, C. D., & Sanders‐Bush, E.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Nichols, Charles D.
- ORCID
- Nichols, Charles D.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2004-06-18
- Volume
- 90
- Issue
- 3
- Pages
- 576-584
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2049004084
- Semantic Scholar
- d814da547100acb8e008d753b1db9192474ae217
- Cited by
- 62
- References
- 32
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 6 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 4
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heffter Research Institute
- National Institute on Drug Abuse (DA05993A, F32DA005993)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- lysergic acid diethylamide, hallucinogens, gene expression, MKP-1, C/EBPβ, arrestin, 5-HT2A receptor, MAPK signaling, transcriptional activation, prefrontal cortex, alternative splicing, splice variants, dose-response relationship
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Hallucinogens, Lysergic Acid Diethylamide, Male, Phosphoprotein Phosphatases, RNA, Messenger, Serotonin Antagonists, Time Factors, Transcriptional Activation, Gene Expression, Protein Tyrosine Phosphatases, Rats, Sprague-Dawley, Prefrontal Cortex, Immediate-Early Proteins, Cell Cycle Proteins, Arrestins, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, CCAAT-Enhancer-Binding Protein-beta, Rats, Dual Specificity Phosphatase 1, Protein Phosphatase 1, Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
